Table 7.
General characteristics and renal replacement of 60 patients with different AKI levels.
| Variables | AKI (n=60) | P-value | Missing | |||
|---|---|---|---|---|---|---|
| AKI-1 (n=38) | AKI-2 (n=7) | AKI-3 (n=15) | Total (n=60) | |||
| COVID-19 Severity | ||||||
| moderate | 10/38 (26.3%) | 0/7 (0%) | 0/15 (0%) | 10/60 (16.7%) | 0.037 | 0 |
| severe | 7/38 (18.4%) | 2/7 (28.6%) | 1/15 (6.7%) | 10/60 (16.7%) | ||
| Critically severe | 21/38 (55.3%) | 5/7 (71.4%) | 14/15 (93.3%) | 40/60 (66.7%) | ||
| Renal recovery | 8/12 (66.7%) | 3/3(100%) | 0/0 (-) | 11/15 (73.3%) | 0.516 | 45 |
| Transferred to ICU | 6/38 (15.8%) | 3/7 (42.9%) | 8/15 (53.3%) | 17/60 (28.3%) | 0.014 | 0 |
| Death | 21/38 (55.3%) | 4/7 (57.1%) | 14/15 (93.3%) | 39/60 (65%) | 0.021 | 0 |
| Proteinuria | 7/15 (46.7%) | 0/3 (0%) | 7/8 (87.5%) | 14/26 (53.8%) | 0.017 | 34 |
| Hematuria | 11/16 (68.8%) | 1/3 (33.3%) | 6/8 (75.0%) | 18/27 (66.7%) | 0.523 | 33 |
| RRT | 3/38 (7.9%) | 2/7 (28.6%) | 6/15 (40.0%) | 11/60 (18.3%) | 0.013 | 0 |
| RRT mode | ||||||
| CVVH | 0/2 (0%) | 0/2 (0%) | 1/5 (20.0%) | 1/9 (11.1%) | >0.999 | 51 |
| CRRT | 2/2 (100%) | 2/2 (100%) | 4/5 (80.0%) | 8/9 (88.9%) | ||
| RRT frequency | ||||||
| ≤1 times/week | 0/2 (0%) | 0/1 (0%) | 1/5 (20.0%) | 1/8 (12.5%) | 0.238 | 52 |
| 1-2 times/week | 0/2 (0%) | 0/1 (0%) | 2/5 (40.0%) | 2/8 (25.0%) | ||
| 2-3 times/week | 0/2 (0%) | 1/1 (100%) | 0/5 (0%) | 1/8 (12.5%) | ||
| ≥4 times/week | 2/2 (100%) | 0/1 (0%) | 2/5 (40.0%) | 4/8 (50.0%) | ||
| Renal replacement time | ||||||
| 2<-4 h | 1/2 (50.0%) | 0/1 (0%) | 0/3 (0%) | 1/6 (16.7%) | >0.999 | 54 |
| 4<-6 h | 1/2 (50.0%) | 1/1 (100%) | 2/3 (66.7%) | 4/6 (66.7%) | ||
| 6<-8 h | 0/2 (0%) | 0/1 (0%) | 1/3 (33.3%) | 1/6 (16.7%) | ||
RRT, renal replacement therapy; CVVH, Continuous Veno Venous Hemofiltration; CRRT, Continuous renal replacement therapy.